The so-called "bioidentical hormones," custom-made formulations of alternatives to FDA-approved estrogen and progestogen drugs, should be considered to have the same safety issues as those associated with traditional postmenopausal hormone therapy (estrogen alone or for women with a uterus, estrogen plus progestogen) until clinical trials can specify the safety and effectiveness of these products, according to a revised position statement on use of postmenopausal hormone therapy from The North American Menopause Society (NAMS).
